authors
- Thaçi, Diamant
- Puig, Lluís
- Reich, Kristian
- Tsai, Tsen-Fang
- Tyring, Stephen
- Kingo, Külli
- Ziv, Michael
- Pinter, Andreas
- Vender, Ronald
- Lacombe, Aude
- Xia, Summer
- Bhosekar, Vaishali
- Gilloteau, Isabelle
- Guana, Adriana
- Blauvelt, Andrew
Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- December 2019
has subject area
- 1103 Clinical Sciences (FoR)
- Adult (MeSH)
- Antibodies, Monoclonal, Humanized (MeSH)
- Dermatologic Agents (MeSH)
- Dermatology & Venereal Diseases (Science Metrix)
- Double-Blind Method (MeSH)
- Humans (MeSH)
- Patient Reported Outcome Measures (MeSH)
- Psoriasis (MeSH)
- Severity of Illness Index (MeSH)
- Time Factors (MeSH)
- Treatment Outcome (MeSH)
- Ustekinumab (MeSH)